<p>加拿大温哥华，2025 年 12 月 24 日（GLOBE NEWSWIRE）——Clearmind Medicine Inc.（纳斯达克：CMND），（法兰克福证券交易所：CWY0）（“Clearmind” 或 “公司”）是一家临床阶段的生物技术公司，专注于发现和开发新型神经塑性药物，以解决主要的未得到充分治疗的健康问题。今天，公司回顾了在推进其主要候选药物 CMND-100 用于治疗酒精使用障碍（AUD）方面取得的显著进展和动力的一年。</p>
<p>在 2025 年，Clearmind 在其 FDA 批准的 CMND-100 的 I/IIa 期临床试验中取得了关键里程碑，这是一种专有的非致幻 MEAI 基础口服化合物，旨在应对 AUD——这一影响全球数百万人的状况，且有效治疗选择有限。</p>
<p><strong>2025 年的主要亮点包括：</strong></p>
<p><strong>临床试验进展：</strong> 在包括耶鲁医学院、约翰霍普金斯大学医学院、特拉维夫索拉斯基医疗中心和哈达萨医疗中心等知名机构启动了多国 I/IIa 期试验。公司成功启动了首次人体给药，完成了第一组的治疗和入组，并报告了积极的安全性和耐受性结果，没有严重不良事件。此外，以色列站点的首批患者已入组并成功给药。此外，Clearmind 完成了第二组的入组和给药，加速了进一步数据读取的进程。</p>
<p><strong>独立安全认可：</strong> 在中期审查后，获得数据和安全监测委员会（DSMB）的一致批准，继续进行 I/IIa 期临床试验，进一步强化了 CMND-100 的良好安全性。</p>
<p><strong>全球足迹扩展：</strong> 通过多项国际专利申请和针对减肥、肥胖、代谢障碍、抑郁症、创伤后应激障碍、焦虑和暴饮暴食行为等适应症的出版物，增强了其非致幻神经塑性专利的知识产权组合和管道。</p>
<p>Clearmind Medicine 的首席执行官 Adi Zuloff-Shani 博士评论道：“2025 年对 Clearmind 来说是一个关键年份，我们转型为临床阶段公司，执行我们的多国试验。这些成就彰显了我们对创新的严谨态度以及我们致力于为成瘾和心理健康挑战提供变革性治疗的承诺。我们感谢我们敬业的团队、临床合作伙伴、研究人员和投资者的坚定支持。”</p>
<p>“展望 2026 年，Clearmind 将继续专注于推进其管道，生成更多临床数据，并探索战略机会，以最大化股东价值和患者影响。”</p>
<p><strong>关于 Clearmind Medicine Inc.</strong></p>
<p>Clearmind 是一家临床阶段的迷幻药物生物技术公司，专注于发现和开发新型迷幻药物，以解决广泛且未得到充分服务的健康问题，包括酒精使用障碍。其主要目标是研究和开发基于迷幻药的化合物，并尝试将其商业化为受监管的药物、食品或补充剂。</p>
<p>公司的知识产权组合目前由十九个专利家族组成，包括 31 项已授予的专利。公司打算在必要时为其化合物申请更多专利，并将保持机会主义，收购更多知识产权以建立其组合。</p>
<p>Clearmind 的股票在纳斯达克以 “CMND” 符号交易，在法兰克福证券交易所以 “CWY0” 符号交易。</p>
<p>欲了解更多信息，请访问：https://www.clearmindmedicine.com 或联系：</p>
<p>投资者关系</p>
<p>invest@clearmindmedicine.com</p>
<p>电话：（604）260-1566</p>
<p>美国：CMND@crescendo-ir.com</p>
<p>一般咨询</p>
<p>Info@Clearmindmedicine.com</p>
<p>www.Clearmindmedicine.com</p>
<p><strong>前瞻性声明：</strong></p>
<p>本新闻稿包含《私人证券诉讼改革法案》和其他证券法意义上的 “前瞻性陈述”。诸如 “预计”、“预期”、“打算”、“计划”、“相信”、“寻求”、“估计” 等词语或类似表达的变体旨在识别前瞻性陈述。例如，公司在讨论推进其主要候选药物 CMND-100 用于治疗酒精使用障碍、致力于提供变革性成瘾和心理健康挑战治疗、推进其产品管线、生成额外临床数据以及探索战略机会以最大化股东价值和患者影响时，使用了前瞻性陈述。前瞻性陈述并非历史事实，而是基于管理层当前的预期、信念和预测，其中许多本质上具有不确定性。这些预期、信念和预测是以诚信表达的。然而，无法保证管理层的预期、信念和预测将会实现，实际结果可能与前瞻性陈述中所表达或指示的内容有重大差异。前瞻性陈述受到风险和不确定性的影响，这可能导致实际表现或结果与前瞻性陈述中所表达的内容有重大差异。有关影响公司的风险和不确定性的更详细描述，请参考公司不时向证券交易委员会（“SEC”）提交的报告，包括但不限于公司截至 2024 年 10 月 31 日的财政年度的 20-F 表格年报中详细列出的风险及随后向 SEC 提交的文件。前瞻性陈述仅在声明发布之日有效。公司不承担更新前瞻性陈述以反映实际结果、后续事件或情况、假设变化或影响前瞻性信息的其他因素变化的义务，除非适用的证券法要求。如果公司更新一项或多项前瞻性陈述，不应推断公司将就此或其他前瞻性陈述进行额外更新。提供的参考和链接仅为方便，网站上包含的信息并未被纳入本新闻稿的引用。Clearmind 对第三方网站的内容不承担责任。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE5qazNPU00zTXpNMU9ETTRJelV3TURBNE5qa3pOQT09?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE5qazNPU00zTXpNMU9ETTRJelV3TURBNE5qa3pOQT09"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZDJhODQ3M2UtZWYxZi00ZWUyLWI4NjktMzEwZmQ0OTVlNmRiLTUwMDA4NjkzNC0yMDI1LTEyLTI0LWVu/tiny/Clearmind-Medicine-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZDJhODQ3M2UtZWYxZi00ZWUyLWI4NjktMzEwZmQ0OTVlNmRiLTUwMDA4NjkzNC0yMDI1LTEyLTI0LWVu/tiny/Clearmind-Medicine-Inc-.png"/></p>

CMND

<p>Clearmind Medicine Inc. 回顾了在 2025 年取得的重大进展，推进了其主要候选药物 CMND-100 用于治疗酒精使用障碍。主要成就包括成功完成 I/IIa 期临床试验、积极的安全性结果，以及全球知识产权组合的扩展。该公司旨在继续推进其研发管线，并在 2026 年探索战略机会</p>

<p>Vancouver, Canada, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the &#34;Company&#34;), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today reflected on a year of significant momentum and progress in advancing its lead candidate, CMND-100, for the treatment of Alcohol Use Disorder (AUD).</p>
<div class="lb-trans"><p>加拿大温哥华，2025 年 12 月 24 日（GLOBE NEWSWIRE）——Clearmind Medicine Inc.（纳斯达克：CMND），（法兰克福证券交易所：CWY0）（“Clearmind” 或 “公司”）是一家临床阶段的生物技术公司，专注于发现和开发新型神经塑性药物，以解决主要的未得到充分治疗的健康问题。今天，公司回顾了在推进其主要候选药物 CMND-100 用于治疗酒精使用障碍（AUD）方面取得的显著进展和动力的一年。</p>
</div><p>Throughout 2025, Clearmind achieved critical milestones in its FDA-approved Phase I/IIa clinical trial for CMND-100, a proprietary non-hallucinogenic MEAI-based oral compound designed to address AUD—a condition affecting millions worldwide with limited effective treatment options.</p>
<div class="lb-trans"><p>在 2025 年，Clearmind 在其 FDA 批准的 CMND-100 的 I/IIa 期临床试验中取得了关键里程碑，这是一种专有的非致幻 MEAI 基础口服化合物，旨在应对 AUD——这一影响全球数百万人的状况，且有效治疗选择有限。</p>
</div><p><strong>Key 2025 highlights include:</strong></p>
<div class="lb-trans"><p><strong>2025 年的主要亮点包括：</strong></p>
</div><p><strong>Clinical Trial Progress:</strong> Advanced the multinational Phase I/IIa trial with site activations at prestigious institutions, including Yale School of Medicine, Johns Hopkins University School of Medicine, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center. The Company successfully initiated first-in-human dosing, completed treatment and enrollment for the first cohort, and reported positive top-line safety and tolerability results with no serious adverse events. Additionally, the first patients in the Israeli sites were enrolled and successfully dosed. Moreover, Clearmind completed enrollment and dosing for the second cohort, accelerating the path toward further data readouts.</p>
<div class="lb-trans"><p><strong>临床试验进展：</strong> 在包括耶鲁医学院、约翰霍普金斯大学医学院、特拉维夫索拉斯基医疗中心和哈达萨医疗中心等知名机构启动了多国 I/IIa 期试验。公司成功启动了首次人体给药，完成了第一组的治疗和入组，并报告了积极的安全性和耐受性结果，没有严重不良事件。此外，以色列站点的首批患者已入组并成功给药。此外，Clearmind 完成了第二组的入组和给药，加速了进一步数据读取的进程。</p>
</div><p><strong>Independent Safety Endorsement:</strong> Received unanimous approval from the Data and Safety Monitoring Board (DSMB) to continue the Phase I/IIa clinical trial following an interim review, reinforcing CMND-100's favorable safety profile.</p>
<div class="lb-trans"><p><strong>独立安全认可：</strong> 在中期审查后，获得数据和安全监测委员会（DSMB）的一致批准，继续进行 I/IIa 期临床试验，进一步强化了 CMND-100 的良好安全性。</p>
</div><p><strong>Global Footprint Expansion:</strong> Strengthened intellectual property portfolio and pipeline of its non-hallucinogenic neuroplastogen patents with multiple international patent filings and publications targeting indications such as weight loss, obesity, metabolic disorders, depression, PTSD, anxiety and binge behaviors.</p>
<div class="lb-trans"><p><strong>全球足迹扩展：</strong> 通过多项国际专利申请和针对减肥、肥胖、代谢障碍、抑郁症、创伤后应激障碍、焦虑和暴饮暴食行为等适应症的出版物，增强了其非致幻神经塑性专利的知识产权组合和管道。</p>
</div><p>Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, commented: “2025 has been a pivotal year for Clearmind as we transitioned into a clinical-stage company, executing on our multinational trial. These achievements underscore our disciplined approach to innovation and our commitment to delivering transformative treatments for addictions and mental health challenges. We are grateful to our dedicated team, clinical partners, investigators, and investors for their unwavering support.”</p>
<div class="lb-trans"><p>Clearmind Medicine 的首席执行官 Adi Zuloff-Shani 博士评论道：“2025 年对 Clearmind 来说是一个关键年份，我们转型为临床阶段公司，执行我们的多国试验。这些成就彰显了我们对创新的严谨态度以及我们致力于为成瘾和心理健康挑战提供变革性治疗的承诺。我们感谢我们敬业的团队、临床合作伙伴、研究人员和投资者的坚定支持。”</p>
</div><p>&#34;Looking ahead to 2026, Clearmind remains focused on advancing its pipeline, generating additional clinical data, and exploring strategic opportunities to maximize shareholder value and patient impact&#34;.</p>
<div class="lb-trans"><p>“展望 2026 年，Clearmind 将继续专注于推进其管道，生成更多临床数据，并探索战略机会，以最大化股东价值和患者影响。”</p>
</div><p><strong>About Clearmind Medicine Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Clearmind Medicine Inc.</strong></p>
</div><p>Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.</p>
<div class="lb-trans"><p>Clearmind 是一家临床阶段的迷幻药物生物技术公司，专注于发现和开发新型迷幻药物，以解决广泛且未得到充分服务的健康问题，包括酒精使用障碍。其主要目标是研究和开发基于迷幻药的化合物，并尝试将其商业化为受监管的药物、食品或补充剂。</p>
</div><p>The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.</p>
<div class="lb-trans"><p>公司的知识产权组合目前由十九个专利家族组成，包括 31 项已授予的专利。公司打算在必要时为其化合物申请更多专利，并将保持机会主义，收购更多知识产权以建立其组合。</p>
</div><p>Shares of Clearmind are listed for trading on Nasdaq under the symbol &#34;CMND&#34; and the Frankfurt Stock Exchange under the symbol “CWY0.”</p>
<div class="lb-trans"><p>Clearmind 的股票在纳斯达克以 “CMND” 符号交易，在法兰克福证券交易所以 “CWY0” 符号交易。</p>
</div><p>For further information, visit: https://www.clearmindmedicine.com or contact:</p>
<div class="lb-trans"><p>欲了解更多信息，请访问：https://www.clearmindmedicine.com 或联系：</p>
</div><p>Investor Relations</p>
<div class="lb-trans"><p>投资者关系</p>
</div><p>invest@clearmindmedicine.com</p>
<div class="lb-trans"><p>invest@clearmindmedicine.com</p>
</div><p>Telephone: (604) 260-1566</p>
<div class="lb-trans"><p>电话：（604）260-1566</p>
</div><p>US: CMND@crescendo-ir.com</p>
<div class="lb-trans"><p>美国：CMND@crescendo-ir.com</p>
</div><p>General Inquiries</p>
<div class="lb-trans"><p>一般咨询</p>
</div><p>Info@Clearmindmedicine.com</p>
<div class="lb-trans"><p>Info@Clearmindmedicine.com</p>
</div><p>www.Clearmindmedicine.com</p>
<div class="lb-trans"><p>www.Clearmindmedicine.com</p>
</div><p><strong>Forward-Looking Statements:</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明：</strong></p>
</div><p>This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses advancing its lead candidate, CMND-100, for the treatment of Alcohol Use Disorder, its commitment to delivering transformative treatments for addictions and mental health challenges, advancing its pipeline, generating additional clinical data, and exploring strategic opportunities to maximize shareholder value and patient impac . Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2024 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.</p>
<div class="lb-trans"><p>本新闻稿包含《私人证券诉讼改革法案》和其他证券法意义上的 “前瞻性陈述”。诸如 “预计”、“预期”、“打算”、“计划”、“相信”、“寻求”、“估计” 等词语或类似表达的变体旨在识别前瞻性陈述。例如，公司在讨论推进其主要候选药物 CMND-100 用于治疗酒精使用障碍、致力于提供变革性成瘾和心理健康挑战治疗、推进其产品管线、生成额外临床数据以及探索战略机会以最大化股东价值和患者影响时，使用了前瞻性陈述。前瞻性陈述并非历史事实，而是基于管理层当前的预期、信念和预测，其中许多本质上具有不确定性。这些预期、信念和预测是以诚信表达的。然而，无法保证管理层的预期、信念和预测将会实现，实际结果可能与前瞻性陈述中所表达或指示的内容有重大差异。前瞻性陈述受到风险和不确定性的影响，这可能导致实际表现或结果与前瞻性陈述中所表达的内容有重大差异。有关影响公司的风险和不确定性的更详细描述，请参考公司不时向证券交易委员会（“SEC”）提交的报告，包括但不限于公司截至 2024 年 10 月 31 日的财政年度的 20-F 表格年报中详细列出的风险及随后向 SEC 提交的文件。前瞻性陈述仅在声明发布之日有效。公司不承担更新前瞻性陈述以反映实际结果、后续事件或情况、假设变化或影响前瞻性信息的其他因素变化的义务，除非适用的证券法要求。如果公司更新一项或多项前瞻性陈述，不应推断公司将就此或其他前瞻性陈述进行额外更新。提供的参考和链接仅为方便，网站上包含的信息并未被纳入本新闻稿的引用。Clearmind 对第三方网站的内容不承担责任。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE5qazNPU00zTXpNMU9ETTRJelV3TURBNE5qa3pOQT09" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYxNjk3OSM3MzM1ODM4IzUwMDA4NjkzNA=="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZDJhODQ3M2UtZWYxZi00ZWUyLWI4NjktMzEwZmQ0OTVlNmRiLTUwMDA4NjkzNC0yMDI1LTEyLTI0LWVu/tiny/Clearmind-Medicine-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/ZDJhODQ3M2UtZWYxZi00ZWUyLWI4NjktMzEwZmQ0OTVlNmRiLTUwMDA4NjkzNC0yMDI1LTEyLTI0LWVu/tiny/Clearmind-Medicine-Inc-.png"/></p>

Clearmind Medicine Reflects on a Transformative 2025: Key Clinical Advancements, Expanded Global Reach, and Strengthened Foundation for Future Growth | CMND Stock News

Clearmind Medicine 回顾变革性的 2025 年：关键的临床进展、全球影响力的扩展，以及为未来增长奠定的坚实基础 | CMND 股票新闻